Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2007

View Archived Issues

Recent patents impart new therapeutic agents for cancer

Recent patents disclose new agents for metabolic disorders

Novel treatment option for respiratory disorders claimed in recent Argenta patent

MEND-CABG II study of MC-1 recommended to continue

CollaGenex discontinues 40 mg cohort in phase II acne study of incyclinide

COSTAR II study fails to meet endpoints

New data indicate Homspera may demonstrate adjuvant capabilities

TorreyPines to sell assets for treating autoimmune diseases to CalciMedica

New bioavailability data for BEMA Fentanyl

Australian TGA accepts Solbec's development plan for Coramsine

Interim three-month data for ISA-247 kidney transplant trial

Preliminary phase IIa data indicate utility of AT-1001 in celiac disease

New data on NX-1207 show sustained symptomatic improvement in BPH

AEterna Zentaris updates clinical progress

European CHMP recommends approval of Siklos

TRPV1 channel as a novel drug target in ocular disorders

Recent clinical data on intravitreal bevacizumab in ophthalmological conditions

Calcineurin inhibitor-free regimen with CP-690550 effective in renal transplantation

Studies show efficacy of lamotrigine in epilepsy

Abatacept associated with reduced flare incidence in juvenile idiopathic arthritis

Vision maintained with combretastatin A-4 in choroidal neovascularization patients

SRI International regains rights to tirapazamine from sanofi-aventis

Omrix seeks Swedish approval for HBIG product

New licensing agreement for NM-702 for arteriosclerosis obliterans

AEterna Zentaris regains rights for cetrorelix from Solvay

Fabre-Kramer amends NDA for gepirone ER in major depressive disorder

Adverse event reported in phase II anemia trial of FG-2216

PAC-113 active in the treatment of oral Candida infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...